Denali Therapeutics Inc. DNLI Business Segments — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s business segments — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s business segments — operating expenses?
- Denali Therapeutics Inc. (DNLI) reported business segments — operating expenses of $137.36M in Q1 2026.
- How has Denali Therapeutics Inc.'s business segments — operating expenses changed year-over-year?
- Denali Therapeutics Inc.'s business segments — operating expenses decreased by 5.6% year-over-year, from $145.58M to $137.36M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — operating expenses?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — operating expenses has grown at a 7.3% compound annual growth rate (CAGR), from $449.21M to $555.34M.
- What does business segments — operating expenses mean?
- The sum of all research, development, and administrative costs incurred during the period. This metric represents the total cash outflow required to sustain the company's operations before accounting for revenue or financing activities. It is a critical measure for evaluating the company's overall operational scale and cash burn.